Navigation Links
CPF Responds to Positive News on First Drug for Treatment for Pulmonary Fibrosis

CULVER CITY, Calif., Dec. 21, 2010 /PRNewswire-USNewswire/ -- The Coalition for Pulmonary Fibrosis (CPF) announced to more than 128,000 patients news that the first drug for the treatment of the deadly lung disease Pulmonary Fibrosis (PF) has passed a major hurdle in the European regulatory process and is likely to be approved in all 27 member countries of the European Union (EU).

The drug, Espriet (Pirfenidone), has received a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the Europeans Medicines Agency (EMA).  The committee recommends the granting of a marketing authorization for the drug in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF), a lethal lung disease characterized by progressive scarring of lung tissue.  The committee's positive opinion will now be forwarded to the European Commission for ratification.  The ratification process typically takes two to three months following the adoption of the CHMP opinion.  

"While this likely EU approval does not mean approval here in the U.S., it does mean that patients will have options in making their treatment decisions," said Mishka Michon, Chief Executive Officer of the CPF.

Esbriet has failed to reach regulatory approval in the U.S and was turned down by the Food & Drug Administration (FDA) earlier this year despite a recommendation by an FDA committee recommending approval of the drug.  

The positive news could mean the first approved therapy to treat PF in the western half of the world.  The drug is already approved in Japan and a generic version has been approved in India.  

PF – a relentlessly progressive and ultimately fatal lung disease affects more than 128,000 people and claims 40,000 lives each year.

The CPF recognizes the decision in the EU could impact the review of the drug in the U.S. as the FDA makes its final decisions on Espriet.  

The CPF which has long advocated on behalf of researchers and patients for accelerated research to treat and cure PF, both by the pharmaceutical industry and research funded by the National Institutes of Health (NIH).  The CPF has also directly funded emerging research at several of the nation's leading centers for the treatment and study of PF including The University of Chicago, University of Michigan, and the David Geffen School of Medicine at UCLA and directed more than $600,000 in combined research funding since 2006 through its partnership with the American Thoracic Society (ATS). Complete details on CPF activities, including research, are available on our web page at:

About Pulmonary Fibrosis (PF)

Pulmonary Fibrosis (PF) is a lung disorder characterized by a progressive scarring – known as fibrosis -- and deterioration of the lungs, which slowly robs its victims of their ability to breathe. Approximately 128,000 Americans suffer from PF, and there is currently no known cause or cure. An estimated 48,000 new cases are diagnosed each year. PF is difficult to diagnose and an estimated two-thirds of patients die within five years of diagnosis.  Sometimes PF can be linked to a particular cause, such as certain environmental exposures, chemotherapy or radiation therapy, residual infection, or autoimmune diseases such as scleroderma or rheumatoid arthritis. However, in many instances, no known cause can be established. When this is the case, it is called idiopathic pulmonary fibrosis (IPF).

About the CPF

The CPF is a 501(c)(3) nonprofit organization, founded in 2001 to accelerate research efforts leading to a cure for pulmonary fibrosis (PF), while educating, supporting, and advocating for the community of patients, families, and medical professionals fighting this disease. The CPF funds promising research into new approaches to treat and cure PF; provides patients and families with comprehensive education materials, resources, and hope; serves as a voice for national advocacy of PF issues; and works to improve awareness of PF in the medical community as well as the general public. The CPF's nonprofit partners include many of the most respected medical centers and healthcare organizations in the U.S. With more than 23,000 members nationwide, the CPF is the largest nonprofit organization in the U.S. dedicated to advocating for those with PF. For more information please visit or call (888) 222-8541.

SOURCE Coalition for Pulmonary Fibrosis
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Marken Rapidly Responds to Global Supply Chain Security Measures
2. PhRMA CEO John Castellani Responds to Mid-Term Election, Stresses Importance of Innovation to Help Grow Economy
3. FRCs Jeanne Monahan Responds to Two New Deaths from RU-486
4. Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S.
5. Atrium Responds to Bard Suit
6. NVHR Responds to New York Times Article on Hepatitis C Testing
7. Takeda Responds to FDA Advisory Committee Recommendation
8. Coalition for Pulmonary Fibrosis Responds to News of Further Review of Pirfenidone By FDA
9. New Science Education Program Responds to Presidents Call to Help Young People Excel in Science
10. GlaxoSmithKline Responds to US Senate Committee on Finance Report on Avandia
11. U.S. Kidney Dialysis Community Responds to Haitis Emergency Plea for Life-Saving Dialysis Care
Post Your Comments:
(Date:11/30/2015)... --> --> According to ... (Soft Tissue, All Tissue, Dental Welding Lasers), Application (Conservative Dentistry, ... Global Forecast to 2020", published by MarketsandMarkets, is expected to ... 5.2% during the forecast period from 2015 to 2020. ... spread through 167 P ages and in-depth TOC on ...
(Date:11/30/2015)... ST. LOUIS , Nov. 30, 2015  Premera ... today announced an early renewal of the companies, long-standing ... will now extend through at least 2019. ... pharmacy benefit manager capabilities during a competitive review and ... offer the best health plan integration and deliver the ...
(Date:11/30/2015)... , Nov. 30, 2015 Booth #4303 – ... VAR ) will exhibit a broader array of products in ... Radiological Society of North America in ... at the meeting will feature X-ray components "At the Heart ... a line of products from Varian,s Claymount brand, and computer-aided ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Healthjump, Inc. announced that ... Healthcare IT consulting, development and support company. The purchase will expand the capability ... DataTrade to extend the services currently provided by Healthjump. , Through ...
(Date:11/30/2015)... Columbia, Maryland (PRWEB) , ... November 30, 2015 ... ... human interactions could be of critical importance to the medical schools of the ... SIMmersion exhibited its healthcare suite at the 2015 ChangeMedEd conference in Chicago, organized ...
(Date:11/30/2015)... ... November 30, 2015 , ... TransPack Volume 6 features 30 customizable transitions created ... web-styled transitions to wipes with blur & drop shadow options. Utilize the controls ... from one clip to the next with TransPack's easily customizable styles. , ...
(Date:11/30/2015)... ... 2015 , ... Innovaacom, a leading provider of medical education ... of educational needs for pharmacists worldwide. The poll of pharmacists in Europe, Asia, ... online and face-to-face education for pharmacists who are fast becoming the new “gatekeepers” ...
(Date:11/30/2015)... 2015 (PRWEB) , ... November ... ... are pleased to announce their strategic partnership at the Radiological Society of ... Inc., and Winscribe, global providers of cutting-edge dictation and speech-enabled documentation software, ...
Breaking Medicine News(10 mins):